Abstract
Left ventricular hypertrophy (LVH) is an independent risk factor for cardiovascular (CV) mortality. The PRECISION trial evaluated the CV safety of celecoxib and nonselective NSAIDs. We assessed the contemporary impact of LVH on CV outcomes diagnosed by EKG in this randomized clinical trial. We
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
